Literature DB >> 12593853

GL331 inhibits HIF-1alpha expression in a lung cancer model.

Hang Chang1, Kou-Gi Shyu, Chun-Chung Lee, Shiow-Chwen Tsai, Bao-Wei Wang, Yu Hsien Lee, Shankung Lin.   

Abstract

We have studied GL331's anti-cancer mechanisms by studying their effect on the tumor-induced angiogenesis. Human lung adenocarcinoma CL1-5 cells were treated with GL331 and then maintained in serum-reduced, GL331-free medium for the preparation of condition mediums. These condition mediums were tested for their capability to induce in vitro angiogenesis, i.e., HUVEC tube formation and migration. We found that mediums generated from GL331-treated CL1-5 cells presented reduced ability of inducing in vitro angiogenesis. Western blot analyses showed that both VEGF and HIF-1alpha were down-regulated in GL331-treated CL1-5 cells. Northern blot and EMSA analyses showed that GL331 down-regulated HIF-1alpha expression without decreasing the stability of HIF-1alpha mRNA, and that GL331 decreased the binding of CL1-5-derived nuclear components to the promoter of HIF-1alpha gene. Therefore, our data showed that GL331 is a potent inhibitor of tumor-induced angiogenesis. The underlying mechanisms might involve at least the inhibition of HIF-1alpha expression, probably through transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593853     DOI: 10.1016/s0006-291x(03)00111-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Authors:  C Lance Cowey; W Kimryn Rathmell
Journal:  Expert Opin Drug Discov       Date:  2008-03       Impact factor: 6.098

2.  Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.

Authors:  Songmi Noh; Ji-Ye Kim; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-05-22

Review 3.  Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.

Authors:  Francisco Javier Rodríguez-Jiménez; Victoria Moreno-Manzano
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

4.  HIF-1alpha: a valid therapeutic target for tumor therapy.

Authors:  Soon-Sun Hong; Hyunseung Lee; Kyu-Won Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

5.  Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma.

Authors:  Yon Hee Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-07-23

6.  The expression of metabolism-related proteins in phyllodes tumors.

Authors:  Ji Eun Kwon; Woo-Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2012-09-18

Review 7.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

8.  Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.

Authors:  Betty K Samulitis; Terry H Landowski; Robert T Dorr
Journal:  Invest New Drugs       Date:  2008-07-08       Impact factor: 3.850

9.  SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor.

Authors:  M Aktar Ali; Hak Choy; Amyn A Habib; Debabrata Saha
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

Review 10.  Development of HIF-1 inhibitors for cancer therapy.

Authors:  Barbara Onnis; Annamaria Rapisarda; Giovanni Melillo
Journal:  J Cell Mol Med       Date:  2009-08-08       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.